35th Annual Report for the year ended 31st March, 2025 .
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Transgene Biotek has filed its 35th Annual Report for the financial year ended 31st March 2025 along with the notice for the 35th Annual General Meeting, scheduled for 30th December 2025 at 11:00 a.m. via video conferencing. The AGM agenda includes adoption of audited accounts, re-appointment of a director retiring by rotation, re-appointment of Dr. K. Koteswara Rao (83 years old) as Chairman & Managing Director for one year via special resolution, re-appointment of three independent directors for a second five-year term, and appointment of M/s. Geeta Serwani as Secretarial Auditor for five years. The Chairman's speech strikes a notably concerning tone, describing 'enormous burden' on management, 'relentless back breaking restrictions', and a hope that transferring technology to NiedlFree Technologies (where the MD is also a director) will 'recoup some of the value that would otherwise have been washed down the drain completely.' He also indicated he plans to step down in FY26 citing health and age.
The Chairman's unusually candid and gloomy remarks suggest the company is navigating serious operational or financial headwinds, which could raise going-concern concerns for retail investors. Shareholders should carefully review the full audited financials, notes, and auditor's report attached to the annual report before the 23rd December 2025 cut-off date for e-voting, and pay close attention to any disclosures about the NiedlFree Technologies technology transfer.